An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Public ClinicalTrials.gov record NCT03338790. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.
Study identification
- NCT ID
- NCT03338790
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 292 participants
Conditions and interventions
Conditions
Interventions
- nivolumab Biological
- docetaxel Drug
- enzalutamide Drug
- rucaparib Drug
- prednisone Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2017
- Primary completion
- Jan 12, 2021
- Completion
- Jan 9, 2025
- Last update posted
- Jan 26, 2026
2017 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 18
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0036 | Daphne | Alabama | 36526 | — |
| Local Institution - 0010 | Rancho Mirage | California | 92270 | — |
| Local Institution - 0049 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0037 | Miami | Florida | 33176 | — |
| Local Institution - 0009 | Marietta | Georgia | 30060 | — |
| Local Institution - 0065 | Louisville | Kentucky | 40207 | — |
| Tulane University | New Orleans | Louisiana | 70112 | — |
| Local Institution - 0040 | Rockville | Maryland | 20850 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Local Institution - 0012 | Detroit | Michigan | 48201 | — |
| Local Institution - 0069 | Jackson | Mississippi | 39202 | — |
| Local Institution - 0011 | St Louis | Missouri | 63110 | — |
| Local Institution - 0035 | Omaha | Nebraska | 68130 | — |
| Local Institution - 0038 | Albany | New York | 12208 | — |
| Local Institution - 0068 | New York | New York | 10032 | — |
| Local Institution - 0041 | Durham | North Carolina | 27710 | — |
| Local Institution - 0024 | Portland | Oregon | 97225 | — |
| Local Institution - 0053 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0039 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03338790, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03338790 live on ClinicalTrials.gov.